The Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market, estimated at USD 173.1 Mn in 2025, is expected to exhibit a CAGR of 10.8% and reach USD 354.9 Mn by 2032.
The market growth is driven by rising demand for accurate and early disease detection, supported by advances in molecular diagnostics, imaging, and point-of-care testing. Growing focus on personalized medicine, supportive healthcare policies, and ongoing R&D investments are creating new opportunities for industry players.
Key market players are focused on adopting growth strategies such as the launch of new products, and this is expected to drive the global methicillin resistant staphylococcus aureus (MRSA) testing systems market growth. For instance, in January 2025, Vela Diagnostics, a supplier of integrated molecular solutions for the diagnosis of infectious diseases and cancer and innovative test in Singapore, announced the CE-IVD launch of Sentosa SA Direct MRSA/SA PCR test, which provides real-time Polymerase Chain Reaction (PCR) qualitative detection of Staphylococcus aureus (SA) and Methicillin-resistant Staphylococcus aureus (MRSA), to aid in the prevention and control of MRSA/SA infections in healthcare settings.
Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2025, as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems regarding transportation of drugs from one place to another.
COVID-19 had a positive impact on the global methicillin resistant staphylococcus aureus (MRSA) testing systems market. For instance, in April 2025, Siemens Healthcare GmbH, is medical device company headquartered in Erlangen, Germany, formally unveiled the RAPIDPoint 500e staphylococcus aureus blood tests for infection, adding to the company's product lineup and supporting COVID-19 initiatives.
Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market: Key Developments
On March 15, 2025, Cepheid, a molecular diagnostics company, announced the launch of its first manufacturing unit in India at Mahadeva Kodigehalli, Bengaluru. The 77,000 square-foot facility will manufacture the company’s industry Xpert Staphylococcus Aureus testing cartridges for India and other countries.
On May 30, 2025, Cepheid, a molecular diagnostics company, secured the CE mark for its molecular in vitro diagnostic test, Xpert NPM1 Mutation. The Xpert NPM1 Mutation test quantifies the mRNA transcripts of the A, B, and D mutations accounting for approximately 90% of NPM1 mutant cases, plus the control gene, and provides an easy and convenient method of assessing response to therapy and improving the management of patients with MRSA.
In April 2025, DiaSorin S.p.A., a multinational biotechnology company that produces and markets in vitro diagnostics reagent kits used in immunodiagnostics and molecular diagnostics in Italy, announced that its Board of Directors had approved and signed a definitive merger agreement for DiaSorin to acquire Luminex Corporation is a biotechnology company which develops, manufactures and markets proprietary biological testing technologies with applications in life-sciences in U.S.